Abstract: As part of a 2015-2018 clinical trial of peramivir treatment for acute
influenza infections in the elderly, an influenza B/Yamagata/16/1988-like isolate harbouring a
Val430Ile neuraminidase (
NA) substitution was recovered from a single patient.
Abstract: In
NA inhibition assays, oseltamivir, zanamivir and peramivir IC50s of the
Val430Ile isolate were 4-, 15- and 16-fold higher compared to a wild-type (WT) strain.
Abstract: In reverse genetics experiments, the
Ile430Val reversion restored the drug susceptible phenotype.
Abstract: Molecular dynamics simulations suggested that
Val430Ile impacts the
NA binding through a mechanism involvin